bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies, Inc. announced record unit sales for its CyPath® Lung diagnostic test, achieving nearly 300% growth in April 2026 compared to April 2025, based on preliminary unaudited data. This strong performance reflects an ongoing increase in demand for noninvasive diagnostics and early cancer detection.
SAN ANTONIO–(BUSINESS WIRE)—- $BIAF #CyPathLung–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growth so far this year continues to exceed the Company’s internal pr